Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Jacques Body

Showing results (41-50 of 133) with videos related to

Pageof 14
Sort By:
Calcified Tissue International|March 3, 2009
Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastasesNathalie Voorzanger-Rousselot, Fabrice Journe, Valérie Doriath, et al.
European Urology|March 26, 2004
Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cellsJean-Claude Dumon, Fabrice Journé, Naïma Kheddoumi, et al.
Breast Cancer Research : BCR|January 19, 2006
Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell linesFabrice Journe, Carole Chaboteaux, Nicolas Magne, et al.
European Journal of Cancer (Oxford, England : 1990)|January 30, 2007
International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patientsJean-Jacques Body, Rob Coleman, Philippe Clezardin, et al.
Breast Cancer Research : BCR|January 15, 2008
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cellsFabrice Journé, Naïma Kheddoumi, Carole Chaboteaux, et al.
Clinical & Experimental Metastasis|August 17, 2006
Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell linesFabrice Journé, Nicolas Magné, Carole Chaboteaux, et al.
Cancer Treatment Reviews|May 29, 2019
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibodyRoger von Moos, Luis Costa, Eva Gonzalez-Suarez, et al.
Breast Cancer Research and Treatment|March 3, 2007
Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activationFabrice Journe, Guy Laurent, Carole Chaboteaux, et al.
Breast Cancer Research : BCR|June 24, 2003
Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragmentsPaul Andreas Compare Cloos, Stephan Christgau, Nina Lyubimova, et al.
Critical Reviews in Oncology/Hematology|June 13, 2017
Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastasesJean-Jacques Body, Geoffrey Quinn, Susan Talbot, et al.
Pageof 14

Showing results (41-50 of 133) with videos related to

Sort By:
Pageof 14
Calcified Tissue International|March 3, 2009
Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastasesNathalie Voorzanger-Rousselot, Fabrice Journe, Valérie Doriath, et al.
European Urology|March 26, 2004
Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cellsJean-Claude Dumon, Fabrice Journé, Naïma Kheddoumi, et al.
Breast Cancer Research : BCR|January 19, 2006
Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell linesFabrice Journe, Carole Chaboteaux, Nicolas Magne, et al.
European Journal of Cancer (Oxford, England : 1990)|January 30, 2007
International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patientsJean-Jacques Body, Rob Coleman, Philippe Clezardin, et al.
Breast Cancer Research : BCR|January 15, 2008
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cellsFabrice Journé, Naïma Kheddoumi, Carole Chaboteaux, et al.
Clinical & Experimental Metastasis|August 17, 2006
Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell linesFabrice Journé, Nicolas Magné, Carole Chaboteaux, et al.
Cancer Treatment Reviews|May 29, 2019
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibodyRoger von Moos, Luis Costa, Eva Gonzalez-Suarez, et al.
Breast Cancer Research and Treatment|March 3, 2007
Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activationFabrice Journe, Guy Laurent, Carole Chaboteaux, et al.
Breast Cancer Research : BCR|June 24, 2003
Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragmentsPaul Andreas Compare Cloos, Stephan Christgau, Nina Lyubimova, et al.
Critical Reviews in Oncology/Hematology|June 13, 2017
Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastasesJean-Jacques Body, Geoffrey Quinn, Susan Talbot, et al.
Pageof 14